Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2823474 | 0.92 | CTSB (0.46) | CHRM1CTSBCTSSCTSLMEN1 | |
| SCHEMBL1308680 | 0.90 | CTSL (0.46) | CTSBCTSSCTSLMEN1KMT2A | |
| SCHEMBL10151699 | 0.88 | CTSB (0.46) | CHRM1CTSBCTSSCTSLMEN1 | |
| SCHEMBL18038887 | 0.88 | CTSL (0.46) | CTSBCTSSCTSLMEN1KMT2A | |
| SCHEMBL1305844 | 0.87 | CTSL (0.48) | CTSBCTSSCTSLNPC1RAB9A | |
| SCHEMBL1305754 | 0.87 | SYK (0.46) | CTSBCTSSCTSLMEN1KMT2A | |
| SCHEMBL3941493 | 0.85 | TSHR (0.47) | CTSBCTSSCTSLNPC1RAB9A | |
| SCHEMBL29761493 | 0.85 | CTSL (0.49) | CTSBCTSSCTSLMEN1KMT2A | |
| SCHEMBL3931249 | 0.85 | CTSL (0.48) | CTSBCTSSCTSLMEN1KMT2A | |
| SCHEMBL13085484 | 0.83 | CTSL (0.49) | CTSBCTSSCTSLNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230137932-A1 | CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230137932-A1 | CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4087571-A1 | CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 | Dana-Farber Cancer Institute, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20220204510-A1 | 2,3-DIHYDRO-1H-PYRROLIZINE-7-FORMAMIDE DERIVATIVE AND APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3805223-A1 | 2,3-DIHYDRO-1H-PYRROLIZINE-7-FORMAMIDE DERIVATIVE AND APPLICATION THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2008100423-A1 | GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| EP-1954287-A2 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080146818-A1 | Dipeptidylpeptidase IV (DPP-IV) inhibitory activity; (2S,4S)-1-[[N-(4-ethoxycarbonylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)); diabetes | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-06-19 | — | — | US | disclosed |
| US-20070265320-A1 | Bicycloamide Derivative | KYORIN PHARMACEUTICAL CO., LTD (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070167501-A1 | Bicyclo derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| WO-2007070173-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1719757-A1 | BICYCLO DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1717225-A1 | BICYCLIC AMIDE DERIVATIVES | Kyorin Pharmaceutical Co., Ltd. (JP) | 2006-11-02 | — | — | EP | disclosed |
| EP-1712547-A1 | BICYCLOESTER DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2006-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | CHRM1 278/4885CTSB 3158/4885CTSS 2971/4885 |
| US-20230137932-A1 | CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 | ERBB2, EGFR, ERBB3 | CHRM1 4491/4885CTSB 1529/4885CTSS 2327/4885 |
| US-20070265320-A1 | Bicycloamide Derivative | DPP4, DPP7, DPP9 | CHRM1 2075/4885CTSB 654/4885CTSS 849/4885 |
| US-20070167501-A1 | Bicyclo derivative | DPP4, DPP7, DPP9 | CHRM1 2816/4885CTSB 1103/4885CTSS 1596/4885 |
| US-20220204510-A1 | 2,3-DIHYDRO-1H-PYRROLIZINE-7-FORMAMIDE DERIVATIVE AND APPLICATION THEREOF | DPYD, EIF2AK2, INF2 | CHRM1 4794/4885CTSB 2754/4885CTSS 3919/4885 |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | MTTP, CETP, FABP2 | CHRM1 4441/4885CTSB 3479/4885CTSS 3410/4885 |
| US-20210061813-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | CHRM1 3298/4885CTSB 456/4885CTSS 573/4885 |
| US-20080146818-A1 | Dipeptidylpeptidase IV (DPP-IV) inhibitory activity; (2S,4S)-1-[[N-(4-ethoxycarbonylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)); diabetes | DPP4, DPP7, DPP3 | CHRM1 3214/4885CTSB 392/4885CTSS 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.